KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $128.7 million.

  • Sarepta Therapeutics' Receivables - Other rose 9382.53% to $128.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.7 million, marking a year-over-year increase of 9382.53%. This contributed to the annual value of $34.6 million for FY2024, which is 1610.74% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Receivables - Other stood at $128.7 million, which was up 9382.53% from $73.3 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Receivables - Other peaked at $128.7 million during Q3 2025, and registered a low of $8000.0 during Q4 2021.
  • Its 5-year average for Receivables - Other is $36.6 million, with a median of $29.1 million in 2021.
  • In the last 5 years, Sarepta Therapeutics' Receivables - Other plummeted by 9997.66% in 2021 and then skyrocketed by 4128750.0% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Receivables - Other (Quarter) stood at $8000.0 in 2021, then skyrocketed by 41287.5% to $3.3 million in 2022, then surged by 800.03% to $29.8 million in 2023, then rose by 16.11% to $34.6 million in 2024, then soared by 271.97% to $128.7 million in 2025.
  • Its last three reported values are $128.7 million in Q3 2025, $73.3 million for Q2 2025, and $55.2 million during Q1 2025.